Showing results (31-40 of 377) with videos related to
Sort By:
Pageof 38
Clinical Breast Cancer|July 1, 2010
Prediction of benefit from adjuvant treatment in patients with breast cancerJennifer Eng-Wong, Claudine IsaacsThe Breast Journal|July 12, 2020
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancerJulie M Collins, Claudine IsaacsFrontiers in Oncology|September 28, 2020
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast CancerKatia Khoury, Antoinette R Tan, Andrew Elliott, et al.Expert Opinion on Medical Diagnostics|March 19, 2013
Novel molecular prognostic markers in breast cancerTrishna Goswami, Minal Shah, Claudine IsaacsBreast Cancer Research and Treatment|October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxanePaula R Pohlmann, Deena Graham, Tianmin Wu, et al.Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.Cancer|September 26, 2023
Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer-related adverse health eventsJean M Mitchell, Thomas DeLeire, Claudine IsaacsClinical Advances in Hematology & Oncology : H&O|April 12, 2021
Neratinib: an option for HER2-positive metastatic breast cancerJoyce A O'Shaughnessy, Ruth O'Regan, Claudine IsaacsClinical Advances in Hematology & Oncology : H&O|April 12, 2021
Neratinib in the early-stage/extended adjuvant breast cancer patientJoyce A O'Shaughnessy, Claudine Isaacs, Ruth O'ReganBreast Disease|July 23, 2011
BRCA1/2 mutations and triple negative breast cancersBeth N Peshkin, Michelle L Alabek, Claudine IsaacsPageof 38